IPCALAB

Feb 13 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• IPCA LABS DEC-QUARTER CONSOL NET PROFIT 2.48 BILLION RUPEES

• IPCA LABS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 22.45 BILLION RUPEES

Source text: ID:nBSEc00yn9

Further company coverage: IPCA.NS

(([email protected];;))

Feb 7 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• RECEIVES TAX ORDER WITH DEMAND OF 9 MILLION RUPEES

Source text: ID:nBSEdW8yV

Further company coverage: IPCA.NS

(([email protected];;))

Dec 4 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• RECEIVED NECESSARY APPROVAL FOR VOLUNTARY CLOSURE OF SUBSIDIARY

Source text: ID:nBSEbrTx82

Further company coverage: IPCA.NS

(([email protected];;))

Nov 14 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• IPCA LABS SEPT-QUARTER CONSOL NET PROFIT 2.29 BILLION RUPEES

• IPCA LABS SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 23.55 BILLION RUPEES

• IPCA LABS - DIVIDEND OF 2 RUPEES PER SHARE

Source text: ID:nBSE57jkvS

Further company coverage: IPCA.NS

(([email protected];))

Sept 30 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• APPROVED ENTERING INTO AGREEMENTS WITH BAYSHORE PHARMACEUTICALS LLC

• PURCHASE OF RIGHTS, TITLE, INTEREST IN PRODUCT, GOODWILL ASSOCIATED WITH 9 ANDAS OF BAYSHORE USA

• PURCHASE FOR $2.7 MILLION

• UNIT TO BUY USA GENERICS FORMULATIONS MARKETING/DISTRIBUTION BUSINESS OF BAYSHORE USA

• UNIT'S DEAL FOR $10 MILLION

Source text for Eikon: ID:nBSENh6PT

Further company coverage: UNLB.NS

(([email protected];;))

Sept 20 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• GOT TAX ORDER UPHOLDING DEMAND OF 5.5 MILLION RUPEES

Source text for Eikon: ID:nBSE9Bqg1V

Further company coverage: IPCA.NS

(([email protected];;))

Aug 13 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• IPCA LABS JUNE-QUARTER CONSOL NET PAT 1.92 BILLION RUPEES

• IPCA LABS JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 20.93 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: IPCA.NS

(([email protected];))

** Shares of Ipca Laboratories IPCA.NS rise as much as 4.04% to 1,207.50 rupees apiece

** The active pharmaceutical ingredients (API) manufacturer reports 67% year-on-year rise in consolidated net profit to 1.80 bln rupees

** Revenue from operations gains 33% to 20.53 bln rupees

** IPCA is among the only five gainers among 19 pharma stocks; pharma index .NIPHARM slips 1.27% as of 2:12 p.m. IST

** The mean recommendation of the 14 analysts tracking IPCA is "hold", median price target at 985 rupees, 18.4% lower than the current price - LSEG data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Oct 31 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• CLASSIFICATION OF USFDA INSPECTION FOR MANUFACTURING FACILITY AT SEZ INDORE, PITHAMPUR

• MANUFACTURING FACILITY AT SEZ INDORE, PITHAMPUR RECEIVED ESTABLISHMENT INSPECTION REPORT

• ESTABLISHMENT INSPECTION REPORT CLASSIFYING MANUFACTURING FACILITY AS VOLUNTARY ACTION INDICATED (VAI)

• FACILITY CONSIDERED TO BE IN MINIMALLY ACCEPTABLE STATE OF COMPLIANCE WITH REGARD TO CGMP

Source text for Eikon: ID:nBSE6scx4v

Further company coverage: IPCA.NS

(([email protected];;))

** Shares of Ipca Laboratories IPCA.NS rise 7.81% to a 14-month high of 1,009 rupees

** Stock top gainer in pharma index .NIPHARM which is down 1.2%

** Co on Friday received voluntary action indicated (VAI) classification from the U.S. Food and Drug Administration (FDA) for its Madhya Pradesh facility

** VAI implies that the U.S. drug regulator will not take regulatory action against the company

** Stock is most active in six months, with a trading volume of 5.05 mln shares as of 1:38 p.m. IST - LSEG data

** Avg rating of 16 analysts close to equivalent of 'hold;' median PT is 865 rupees

** Stock last up ~6.8%, taking YTD gains to ~19%, compared to 18.5% rise in pharma index

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

Aug 24 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• USFDA INSPECTION UPDATE OF PIPARIA FORMULATIONS MANUFACTURING FACILITY

• US FDA HAVE DETERMINED INSPECTION CLASSIFICATION OF MANUFACTURING FACILITY AS "VOLUNTARY ACTION INDICATED

• FACILITY CONSIDERED TO BE IN MINIMALLY ACCEPTABLE STATE OF COMPLIANCE WITH REGARDS TO CURRENT GOOD MANUFACTURING PRACTICE

Source text for Eikon: ID:nBSE76D1jM

Further company coverage: IPCA.NS

(([email protected];))

Aug 10 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• IPCA LABORATORIES LTD - RE-APPOINTS PRANAY GODHA AS MD

Source text for Eikon: ID:nBSECZd1z

Further company coverage: IPCA.NS

(([email protected];;))

Aug 2 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• AFTER CCI APPROVAL, CO ACQUIRED ABOUT 33.38% OF PAID UP EQUITY SHARE CAPITAL OF UNICHEM LABORATORIES

• DEAL FOR 9.45 BILLION RUPEES

Source text for Eikon: ID:nBSEVdzbP

Further company coverage: IPCA.NS

(([email protected];;))

July 27 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• COMPETITION REGULATOR APPROVES ACQUISITION OF UPTO 59.38% STAKE OF UNICHEM LABORATORIES BY IPCA LABORATORIES

Source text for Eikon: [ID:]

Further company coverage: IPCA.NS

(([email protected];))

June 23 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• US FDA CONDUCTED INSPECTION OF CO'S FORMULATIONS MANUFACTURING FACILITY SITUATED AT PITHAMPUR

• AT CLOSE OF INSPECTION US FDA ISSUED FORM 483 WITH 8 OBSERVATIONS

Source text for Eikon: ID:nBSE26c06

Further company coverage: IPCA.NS

(([email protected];))

** Shares of Ipca Laboratories Ltd IPCA.NS fall as much as 3.1% to 712.4 rupees, biggest intraday pct loss since April 26

** Pharmaceutical firm says USFDA issued 11 observations at the conclusion of inspection at IPCA's manufacturing facility in Madhya Pradesh state

** "Will submit response on observations to USFDA and shall work with agency to resolve issues at the earliest" - IPCA

** Stock trading below its 50-, 100-, and 200-day moving averages

** Trading volume at ~521,200 shares, 0.9x the 30-day avg of ~610,700 shares as of 9:40 a.m. IST

** Average rating of 19 analysts covering stock equivalent of "hold"; median PT is 865 rupees - Refinitiv data

** Including session's losses, stock last down nearly 14% so far this year

(Reporting by Biplob Kumar Das in Bengaluru)

(([email protected]))

May 29 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• MARCH-QUARTER CONSOL NET PROFIT 765.2 MILLION RUPEES VERSUS 1.3 BILLION RUPEES YEAR AGO

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 15.12 BILLION RUPEES VERSUS 12.89 BILLION RUPEES YEAR AGO

Source text for Eikon: ID:nBSE7ZyYgL

Further company coverage: IPCA.NS

(([email protected];))

April 27 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• US FDA CONDUCTED INSPECTION OF CO'S FORMULATIONS MANUFACTURING UNIT SITUATED AT PIPARIA

• US FDA ISSUED A FORM 483 WITH 3 OBSERVATIONS

Source text for Eikon: ID:nBSE3CFsKW

Further company coverage: IPCA.NS

(([email protected];;))

BENGALURU, April 25 (Reuters) - Shares of Indian pharmaceutical firm Ipca Laboratories IPCA.NS fell as much as 9.1% to a near three-year low on Tuesday, after it agreed to buy a 33.38% stake in Unichem Laboratories UNLB.NS for up to 10.34 billion rupees ($126.3 million).

($1 = 81.8700 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru; Editing by Sonia Cheema)

(([email protected]; +91 7982114624;))

April 24 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• APPROVED ENTERING INTO DEFINITIVE SHARE PURCHASE AGREEMENT FOR ACQUISITION OF 33.38% STAKE IN UNICHEM LABORATORIES

• DEAL FOR 10.34 BILLION RUPEES

• ALSO APPROVED MAKING OPEN OFFER TO PUBLIC SHAREHOLDERS OF UNCIHEM LABS TO ACQUIRE UP TO 26% STAKE FOR 8.05 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: IPCA.NS

(([email protected];;))

April 18 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• LYKA LABS LTD - CONSIDERED ISSUE OF 2.4 MILLION SHARES UPON CONVERSION OF WARRANTS TO IPCA LABORATORIES

Source text for Eikon: ID:nBSE2W4l8J

Further company coverage: IPCA.NS

(([email protected];))